1. Immune status during albendazole therapy for hydatidosis
- Author
-
H. Radwan, G. N. Awar, Robert M. Matossian, Philip S. Craig, and G. A. Meshefedjian
- Subjects
0301 basic medicine ,Adult ,Male ,Hemagglutination ,Adolescent ,medicine.medical_treatment ,030231 tropical medicine ,Helminthiasis ,Antibodies, Helminth ,Antigen-Antibody Complex ,Albendazole ,Serology ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Immunity ,Echinococcosis ,medicine ,Animals ,Humans ,Chemotherapy ,biology ,business.industry ,030108 mycology & parasitology ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Echinococcus ,Infectious Diseases ,Hemagglutinins ,Immunoglobulin M ,Immunoglobulin G ,Immunology ,biology.protein ,Parasitology ,Female ,Antibody ,business ,medicine.drug - Abstract
Immunological monitoring of cystic hydatid patients undergoing medico-surgical management has revealed that it is possible to assess individual host responses throughout therapy and subsequently be guided by the results obtained. The analysis has involved the demonstration of variation in haemagglutination antibodies, specific IgG and IgM immunoglobulins and circulating immune complexes before, during, and months after albendazole therapy.
- Published
- 1992